Riociguat

Definition

An orally bioavailable stimulator of soluble guanylate cyclase (sGC), with vasodilating activity. Upon oral administration, riociguat directly stimulates the catalytic activity of sGC. In addition, riociguat stabilizes the binding of nitric oxide (NO) to sGC. Altogether this stimulates the NO-sGC-cyclic guanosine monophosphate (cGMP) pathway and increases the formation of the intracellular second messenger cGMP, which results in smooth muscle relaxation and vasodilation. sGC, a heme-containing cytoplasmic signaling enzyme, catalyzes the formation of cGMP from guanosine triphosphate (GTP) in response to NO binding to heme. Riociguat stimulates sGC independently of and synergistically with NO.

Also known as Adempas, BAY 63-2521, BAY-63-2521, BAY63-2521, RIOCIGUAT — per NCIT

Also identified as

• ATC C02KX05 per RXNORM
• NCIT NCIT:C152225 per NCIT
• SCTID 713333001 per RXNORM
• SCTID 715490004 per RXNORM
• UNII RU3FE2Y4XI per RXNORM

Indications